ASCT vs Bortezomib-Melphalan-Prednisone, With or Without Bortezomib-Lenalidomide-Dexamethasone Consolidation, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Autologous Haematopoietic Stem-Cell Transplantation Versus Bortezomib-Melphalan-Prednisone, With or Without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study
Lancet Haematol 2020 Apr 30;[EPub Ahead of Print], M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, L Dozza, B van der Holt, S Zweegman, S Oliva, VHJ van der Velden, E Zamagni, GA Palumbo, F Patriarca, V Montefusco, M Galli, V Maisnar, B Gamberi, M Hansson, A Belotti, L Pour, P Ypma, M Grasso, A Croockewit, S Ballanti, M Offidani, ID Vincelli, R Zambello, AM Liberati, NF Andersen, A Broijl, R Troia, A Pascarella, G Benevolo, MD Levin, G Bos, H Ludwig, S Aquino, AM Morelli, KL Wu, R Boersma, R Hajek, M Durian, PA von dem Borne, T Caravita di Toritto, C Driessen, G Specchia, A Waage, P Gimsing, UH Mellqvist, M van Marwijk Kooy, M Minnema, C Mandigers, AM Cafro, A Palmas, S Carvalho, A Spencer, M Boccadoro, P SonneveldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.